Share on LinkedInShare on LinkedIn

ARTICLE · 04 JULY 2011

Intellectual Property Weekly Abstracts Alert - Week Of June 27, 2011

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

This was a motion for an interlocutory injunction. The Court first dealt with a motion by AstraZeneca to strike an affidavit filed by Apotex. The Court dismissed the motion.

CanadaIntellectual Property

Edited by Chantal Saunders and Beverley Moore

ACTIONS

Interlocutory Injunction Denied

Astrazeneca Canada Inc. v. Apotex Inc.

Drug: NEXIUM esomeprazole

This was a motion for an interlocutory injunction. The Court first dealt with a motion by AstraZeneca to strike an affidavit filed by Apotex. The Court dismissed the motion. The Court then addressed a motion by Apotex to file a supplementary affidavit. The Court allowed the affidavit to be filed. The Court also made observations about certain arguments made by the parties, "in the interest of discouraging similar statements and certain related hyperbole in the future."

With respect to the motion for an injunction, after setting out the tri-partite test, the Court found that there is a serious issue to be tried. After reviewing the evidence and the arguments made, the Court held that AstraZeneca failed to demonstrate irreparable harm. Further, the Court concluded that AstraZeneca had not demonstrated

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from